ED as a Cardiovascular Warning Sign: the labs that confirm it

Erectile dysfunction is rarely just a sexual problem. In men under 60, new-onset ED is one of the earliest clinical signals of systemic vascular disease — often appearing 3 to 5 years before a coronary event. Treating the symptom without checking the system is a missed opportunity.

This is the framework we use to think about ED as a vascular biomarker, and the specific labs that tell you whether the problem is endothelial, metabolic, hormonal, or some combination of the three.

Why the penis is a vascular early-warning system

The honest mechanical truth. An erection is a hemodynamic event. It requires healthy endothelium, intact nitric oxide signaling, and arteries that can dilate on demand. The cavernosal arteries of the penis are roughly 1–2 mm in diameter. The coronary arteries are 3–4 mm. The carotids are larger still.

When systemic endothelial dysfunction starts — the early, silent phase of atherosclerosis — the smallest arteries lose function first. That's the penis. Which is why the Princeton III Consensus and multiple cohort studies (Inman et al., Mayo Clin Proc 2009; Dong et al., J Am Coll Cardiol 2011) have shown ED independently predicts future cardiovascular events, with a relative risk of roughly 1.4–1.6 for major adverse cardiac events.

In plain English: if a 45-year-old man develops ED, his cardiovascular risk just went up, and the clock on his next decade started ticking faster.

What ED is actually telling you

ED in a younger or middle-aged man usually points to one of four underlying issues, often layered:

• Endothelial dysfunction — impaired nitric oxide bioavailability, the earliest vascular lesion
• Atherosclerosis — established plaque narrowing arterial flow
• Metabolic dysfunction — insulin resistance, visceral adiposity, prediabetes
• Hypogonadism — low testosterone reducing libido and erectile tissue health

Psychogenic ED exists, but it's a diagnosis of exclusion. If erections are absent on waking, absent with masturbation, and gradual in onset, the problem is biological until proven otherwise.

The labs that actually confirm the cause

What we'd want to see on paper. If you're working up ED seriously, the panel below covers the four buckets above. You don't need every marker on day one, but this is what a thorough workup would typically include.

Lipid and atherosclerosis panel

• ApoB — the single best marker of atherogenic particle count. Target generally <90 mg/dL for primary prevention; <80 if other risk factors stack.
• LDL-C and non-HDL-C — still useful, but ApoB is the upgrade.
• Lp(a) — genetic, measured once in a lifetime. Elevated Lp(a) (>50 mg/dL or >125 nmol/L) roughly doubles cardiovascular risk and is often missed.
• Triglycerides and HDL — a TG/HDL ratio >3 suggests insulin resistance.

Metabolic panel

• Fasting glucose and HbA1c — diabetes triples ED risk and accelerates the vascular timeline. A1c >5.7% deserves attention.
• Fasting insulin and HOMA-IR — catches insulin resistance years before A1c moves.
• hs-CRP — low-grade inflammation; >2 mg/L flags elevated vascular risk.

Hormonal panel

• Total testosterone (morning draw, ideally two separate days)
• Free testosterone — calculated or measured; often more informative than total
• SHBG — modifies how to interpret total T
• LH and FSH — distinguishes primary from secondary hypogonadism
• Estradiol (sensitive assay) — relevant if symptoms or T levels are off
• Prolactin — rules out the rare but treatable pituitary cause
• TSH — thyroid dysfunction can present as low libido and fatigue

Optional but informative

• Homocysteine — endothelial stress marker
• Vitamin D — deficiency correlates with ED in observational data
• Coronary artery calcium (CAC) score — not a lab, but the imaging study that often closes the loop in a man with ED plus elevated ApoB

{callout: The takeaway} ED in a man under 60 should trigger a cardiovascular workup, not just a prescription for a PDE5 inhibitor — because the erection is the symptom, and the artery is the disease.

How to read the panel together

The pattern matters more than any single number. A few common phenotypes we see:

The metabolic phenotype. Waist circumference up, triglycerides up, HDL down, A1c creeping into the 5.7–6.2 range, fasting insulin elevated, testosterone low-normal (often because SHBG is suppressed). ED here is driven by insulin resistance and endothelial dysfunction. The fix is metabolic — weight loss, resistance training, sometimes a GLP-1 — and testosterone often recovers on its own once visceral fat drops.

The atherogenic phenotype. Normal weight, normal glucose, but ApoB is 110, LDL-C is 160, and Lp(a) is elevated. ED here is a flow problem. The answer is lipid management and a CAC score to quantify existing plaque.

The hypogonadal phenotype. Symptoms of low T (low libido, low morning erections, fatigue, mood), confirmed low total and free testosterone on two morning draws, with appropriate LH/FSH context. ED here may improve with treatment of the underlying hormone deficit — but cardiovascular risk still needs its own workup.

Most real patients are some blend of all three.

Why a PDE5 inhibitor alone is undertreatment

Sildenafil and tadalafil work. They're effective in roughly 60–70% of men with ED across trials, and they're safe in the vast majority. But they treat the downstream signal — they don't reverse endothelial dysfunction, they don't lower ApoB, and they don't address the metabolic substrate.

A man who gets a PDE5 prescription and nothing else has had his symptom treated and his disease ignored.

The better protocol is: treat the symptom so the patient has a functional sex life now, and run the workup that tells you what's driving it, and fix the upstream drivers over the next 6–12 months.

What changes after the workup

Tuned to your numbers. Depending on what the panel shows, the plan might include:

• A PDE5 inhibitor for symptomatic relief (daily low-dose tadalafil or as-needed sildenafil are the two main published approaches)
• Lipid management — statin, ezetimibe, or a PCSK9 inhibitor depending on ApoB and Lp(a)
• Metabolic intervention — nutrition, training, and a GLP-1 if BMI and metabolic markers justify it
• Testosterone therapy if confirmed hypogonadism is present and other causes are addressed
• Lifestyle levers with real evidence — Mediterranean-pattern eating, 150+ minutes of moderate cardio weekly, resistance training 2–3x/week, sleep apnea screening if indicated

The labs aren't a hoop to jump through. They're the map that tells you which of these levers will actually move the needle for you.

When to escalate

See a clinician promptly — not just for ED, but for cardiovascular workup — if you have:

• New ED before age 50
• ED plus chest pain, exertional shortness of breath, or claudication
• ED plus a strong family history of early cardiac events
• ED plus known diabetes, hypertension, or elevated LDL

These aren't reasons to panic. They're reasons to get the data, build the plan, and stop guessing.

The bottom line

Erectile dysfunction is a vascular biomarker that happens to be embarrassing to talk about. Treated as a sexual complaint, it leads to a prescription. Treated as a cardiovascular signal, it leads to a workup that can change the trajectory of the next 20 years.

The labs above are how you tell which conversation you're actually having.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.